Browse the evidence

Prolonged, intense weight-bearing exercise can increase intestinal permeability but effects are transient.

While intense exercise can temporarily affect gut health, these effects are not long-lasting.

Semaglutide treatment resulted in lower rates of non-CV death, primarily due to fewer infectious deaths (HR: 0.71; 95% CI: 0.51-0.98).

Reducing infectious deaths may be a significant benefit of semaglutide in this population.

Among participants who developed COVID-19, those treated with semaglutide had fewer COVID-19-related serious adverse events and deaths (HR: 0.66; 95% CI: 0.44-0.96).

Semaglutide may provide protective benefits against severe outcomes from COVID-19 in this population.

The cost needed to treat per 1% of body weight reduction with tirzepatide is estimated at $985 compared with $1845 with semaglutide.

Tirzepatide is more cost-effective for achieving weight loss in this population.

Active GLP-1 RA prescription was associated with a significant reduction in postoperative hematoma (RR: 0.440; P = 0.023).

Consideration of GLP-1 RA may help in minimizing hematoma risks in surgical patients.

Having a normal body weight does not automatically imply preserved metabolic health.

Practitioners should assess metabolic health beyond just body weight.

There is evidence for the presence of metabolically unhealthy normal weight (MUHNW) and metabolically healthy obese (MHO) phenotypes.

Understanding these phenotypes can guide personalized treatment approaches.

Short-acting GLP-1 receptor agonists are associated with an increased risk of erosive reflux disease (ERD) with a hazard ratio (HR) of 1.215.

Clinicians should be cautious when prescribing short-acting GLP-1 RAs to patients with type 2 diabetes due to the increased risk of ERD.

Short-acting GLP-1 receptor agonists are associated with an increased risk of oesophageal stricture with a hazard ratio (HR) of 1.284.

Healthcare providers should monitor for signs of oesophageal stricture in patients using short-acting GLP-1 RAs.

Short-acting GLP-1 receptor agonists are associated with an increased risk of Barrett's esophagus with dysplasia with a hazard ratio (HR) of 1.505.

Clinicians should be aware of the potential risk of Barrett's esophagus with dysplasia in patients prescribed short-acting GLP-1 RAs.

Machine learning techniques can enhance the ability to forecast obesity outcomes accurately.

Implementing machine learning can lead to better early detection and prediction of obesity.

The exercise goal of 10,000 steps/day was unachievable for the participants.

Practitioners should consider setting realistic exercise goals for pregnant women to enhance adherence.

GLP-1 receptor agonists (GLP-1RAs) are associated with accelerated facial aging and altered skin health.

Clinicians should be aware of the potential for accelerated facial aging in patients treated with GLP-1RAs.

The accelerated facial aging observed in GLP-1RA patients is multifactorial, involving loss of dermal and subcutaneous white adipose tissue.

Understanding the multifactorial nature of aging can guide treatment approaches for affected patients.

Treatment strategies targeting adipose-derived stem cell (ADSC) stimulation may mitigate facial aging effects from GLP-1RAs.

Clinicians may consider ADSC-targeted treatments to improve skin health in patients using GLP-1RAs.

More studies are needed to support the long-term effects of long-acting amylin analogues in relevant populations.

Practitioners should be aware that while promising, the long-term efficacy of these treatments is not yet established.

The analysis was limited to studies using dual-energy X-ray absorptiometry (DXA) for measuring fat-free mass.

Practitioners should be aware of the limitations of DXA in assessing body composition.

The relationship between BMI and LDL cholesterol change was not observed on higher-carbohydrate diets.

Practitioners should consider that the effects of BMI on LDL cholesterol may differ with carbohydrate intake levels.

Perioperative semaglutide use is associated with increased residual gastric content (RGC) in patients undergoing elective esophagogastroduodenoscopy.

Clinicians should consider the timing of semaglutide administration in relation to elective procedures to mitigate RGC risk.

The contribution of the GIP receptor-activating component of tirzepatide to its effects is uncertain.

Further research is needed to clarify how GIP receptor activation contributes to the effects of tirzepatide.

The implementation of MBSAQIP and ERAS protocols has significantly improved the quality of care for all bariatric patients.

Healthcare providers should adopt MBSAQIP and ERAS protocols to enhance patient outcomes.

GLP-1 RAs showed long-term protective effects on renal outcomes and adverse events.

GLP-1 RAs may provide long-term benefits for kidney health in obese individuals without T2D.

Collagen supplementation did not change integrated MPS rates compared to the RDA.

Collagen may not be effective for enhancing muscle protein synthesis in older males.

GIPR agonism may reduce gastrointestinal adverse effects associated with GLP-1R agonism.

GIPR agonists may help mitigate gastrointestinal side effects for patients using GLP-1R agonists.